Retatrutide Research Overview: Three Receptors, Trial Designs and Lot Records

Retatrutide differs from most compounds in this Journal. Where the BPC-157 research overview deals with a literature that is almost entirely preclinical, retatrutide has a controlled human trial program still in progress. This profile describes how that research was designed and what it measured. For any individual batch, the analytical side lives in the LIV More Lot Passport, where each lot’s purity, amount, test date and certificate are filed against the lot number printed on the vial.

Both profiles are listed in the Journal archive.

Every finding below is labeled by study type, and no study amounts or outcome figures are restated.

What retatrutide is

Retatrutide is a single peptide chain of 39 residues, built on an incretin-style backbone and engineered with non-coded amino acids that are not among the 20 standard ones. A C20 fatty diacid side chain is attached to the peptide. In this class of molecule, a lipid side chain of that kind is used to extend circulating half-life through reversible binding to albumin.

The compound was described in a 2022 discovery paper in Cell Metabolism written by scientists at Eli Lilly and Company, its developer. Early papers use the code LY3437943, and later trial reports use the name retatrutide.

These distinctions have practical weight. A certificate for a lipidated peptide has to account for the backbone, the side chain and the counterion, and a mismatch in any one of them shifts the expected analytical values.

How retatrutide acts at three receptors

Retatrutide was designed as a triple agonist. The discovery paper reports that in vitro, LY3437943 showed balanced activity at the glucagon and GLP-1 receptors and greater activity at the GIP receptor. The authors describe the rationale as combining receptor pathways linked to lower food intake with glucagon receptor activity linked to energy expenditure, and they tested that idea in obese mice.

The three targets are class B G protein-coupled receptors, and activity at them is usually measured as cyclic AMP signaling in cell lines engineered to express each receptor. Relative activity across the three receptors is what distinguishes retatrutide from single agonists acting on the GLP-1 receptor and from dual agonists acting on the GIP and GLP-1 receptors.

For analysts, the working point is that “balanced” and “more active” describe results under stated laboratory conditions, not fixed properties that hold in every model.

What published retatrutide research examines

The record moves in the usual order for a drug candidate: cells and animals first, then trials of increasing size. Each item below names the design and what was measured.

• In vitro and animal model, with a first human study. The discovery paper reported receptor activity in vitro and body weight and glycemic measures in obese mice. It also included a phase 1 single ascending dose study assessing safety, tolerability and pharmacokinetics.
• Phase 1b, type 2 diabetes. Urva and colleagues ran a double-blind, placebo-controlled proof of concept study with multiple dose cohorts and dulaglutide as a comparator. It assessed safety, tolerability, pharmacokinetics and pharmacodynamic measures.
• Phase 2, obesity. Jastreboff and colleagues ran a 48-week double-blind, randomized, placebo-controlled trial in adults with obesity, or with overweight plus a weight-related condition. The primary end point was percentage change in body weight at 24 weeks.
• Phase 2, type 2 diabetes. Rosenstock and colleagues compared retatrutide with placebo and with dulaglutide in a double-blind, double-dummy design. The primary endpoint was change in HbA1c at 24 weeks, with HbA1c and body weight at 36 weeks as secondary endpoints.
• Phase 2a substudy, liver fat. Sanyal and colleagues analyzed participants from the obesity trial who had elevated liver fat at baseline. The primary objective was relative change in liver fat at 24 weeks.
• Phase 3, type 2 diabetes. The TRANSCEND-T2D-1 trial was a 40-week, double-blind, placebo-controlled study of retatrutide on its own in adults whose type 2 diabetes was not controlled by diet and exercise. The primary endpoint was change in HbA1c, and percentage change in body weight was a key secondary endpoint.

The larger TRIUMPH phase 3 program, whose design paper describes four trials in more than 5800 participants, evaluates weight management together with obstructive sleep apnea and knee osteoarthritis in a basket design. The conclusions of every trial belong to its authors and sponsor.

What the retatrutide literature does not establish

A large trial program can make a compound look more settled than it is. The limits here are different from those of a preclinical literature, but they are just as real.

• No approval. Retatrutide is investigational. The published trials describe a medicine under clinical development, and no regulator has approved it for any human or veterinary use.
• Trial findings belong to the trial product. Each trial studied a pharmaceutical product made to clinical manufacturing standards and given under protocol with medical oversight. Its results say nothing about material supplied for laboratory research.
• The phase 3 record is incomplete. Most registrational trials in the program had not been published in full by the date of this profile. Company announcements and conference summaries are not peer-reviewed publications.
• One sponsor. The discovery work and the trials cited here were funded by the developer. That is normal for a drug candidate, and it also means independent replication has not yet taken place.
• Animal and in vitro results are not clinical ones. Receptor potency in engineered cell lines and body weight in obese mice are laboratory measurements. They do not predict effects in any individual.

Regulatory context shapes how any of this can be written. Under 21 CFR 201.128, intended use is judged by the objective intent of the people responsible for an article, as shown through labeling claims, advertising and the circumstances of distribution. The Journal therefore describes study designs and measurements and stops there, and it restates no doses or outcome figures from any trial.

Reading a certificate for a retatrutide lot

A certificate of analysis is the document that ties a physical vial to analytical data. A lipidated peptide of 39 residues is a harder analytical subject than a short unmodified peptide, and a good certificate shows it.

Identity by mass is the first check. A molecule of this size appears in electrospray spectra as several charge states at once, so the certificate should say whether the reported mass is a deconvoluted value and which form it refers to. HPLC purity is the second. The lipid side chain makes the molecule strongly retained on reversed-phase columns, and related impurities can include deletion sequences and variants of the side chain, so the chromatogram for the same lot matters as much as the percentage. Amount is the third. Lots of the same compound can be filled at different amounts, so the stated amount should be read from the lot’s own record, not from memory of a previous vial.

• Lot number on the certificate matches the vial label
• Stated form names the peptide and any counterion
• Observed mass agrees with the expected mass, stated as deconvoluted or as a named ion
• HPLC result and chromatogram are attached for the same lot
• Peptide content, if reported, is kept separate from HPLC purity
• Stated amount per vial matches the label on that lot
• Testing laboratory and test date are identified

The research use policy and the terms of sale set out the only terms on which LIV MORE LLC supplies research material. Storage and delivery are covered on the shipping and returns page, and recurring documentation questions are answered in the site FAQ.

To see how these fields appear on a real document, open the retatrutide entry in the Lot Passport, including any earlier lots listed under it, and check each item above against the record for each batch.

Frequently asked questions